Literature DB >> 21338590

Membrane-delimited proteolytic regulation of opioid receptors.

Elena Kaplan1, Binyamin Binyaminy, Mikhal Gafni, Ora Keren, Yosef Sarne.   

Abstract

Prolonged exposure of opioid receptors to agonists leads to their regulation by the classical process of clathrin-dependent internalization, followed by their intracellular degradation (down regulation). We have previously shown that the opioid agonist etorphine induced an additional process of down regulation of mu-opioid receptors (MOR) that occurred in intact MOR-transfected HEK-293 cells, as well as in isolated membranes. In the present study we show that etorphine similarly down regulated rat kappa-opioid receptors (KORs), which do not undergo the classical process of internalization and down regulation. This process was resistant to inhibitors of clathrin-coated pit formation (hypertonic sucrose, mono-dansyl-cadaverine) and was mainly mediated by membranous serine- and amino-peptidases. We further show that various opioid ligands, besides etorphine, induced down regulation of either KOR or MOR in isolated membranes. The ability of the various opioid ligands to induce membrane-delimited KOR or MOR down regulation did not correlate to their classical pharmacological profile, suggesting functional selectivity of the effect. Levorphanol, but not its stereoisomer dextrophan, induced membrane-delimited down regulation of both KOR and MOR, indicating that stereoselective binding to the receptor was necessary to initiate the process. Our findings that this proteolytic regulation of opioid receptors occurs not only in isolated membranes but also in intact cells and that it occurs even when the receptors are resistant to the conventional process of down regulation indicate its possible physiological role in the regulation of opioid activity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21338590     DOI: 10.1016/j.brainres.2011.02.040

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Nalbuphine alleviates inflammation by down-regulating NF-κB in an acute inflammatory visceral pain rat model.

Authors:  Dijiao Ruan; Yuanyuan Wang; Sisi Li; Chao Zhang; Wenwen Zheng; Cong Yu
Journal:  BMC Pharmacol Toxicol       Date:  2022-06-01       Impact factor: 2.605

2.  Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.

Authors:  Yi Zheng; Samuel Obeng; Bethany A Reinecke; Chongguang Chen; Palak S Phansalkar; David M Walentiny; Phillip M Gerk; Lee-Yuan Liu-Chen; Dana E Selley; Patrick M Beardsley; Yan Zhang
Journal:  Eur J Pharmacol       Date:  2019-11-16       Impact factor: 4.432

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.